AI Drug Discovery for Pharma and Biotech

Drug discovery

1

drug

With orphan designation

Overview

Osteonecrosis of the jaw (ONJ) is a rare but serious condition characterized by exposed, non-healing jawbone due to impaired vascular supply, often associated with antiresorptive (bisphosphonates, denosumab) or antiangiogenic therapies. It typically manifests as pain, exposed bone (>8 weeks), and infection, with highest incidence in oncology patients receiving high-dose IV therapy. Management involves staged approaches, emphasizing early diagnosis and multidisciplinary care to prevent progression [1][3][9][14].

Population

  • Highest risk in cancer patients receiving IV bisphosphonates (1-15% incidence) or denosumab, particularly with dental trauma, glucocorticoid use, or poor oral hygiene [2][10][14].

  • Lower risk in osteoporosis patients (0.001%-0.1%) using oral/intravenous antiresorptives [6][18].

Burden

  • Significantly impacts quality of life, causing chronic pain, dysphagia, and disfigurement [9][14].

  • Incidence rises with prolonged antiresorptive use: ~1% at 1 year, 3% at 3 years in cancer patients [10], reaching 9% in metastatic breast cancer cohorts [14].

  • Treatment costs and morbidity escalate in advanced stages due to complex surgical needs and prolonged antimicrobial therapy [4][7][12].

Therapies

  • Conservative: Antibiotics (e.g., penicillin, clindamycin), chlorhexidine rinses, and analgesia for early stages (0–2) [8][12][15].

  • Surgical: Debridement or resection for advanced non-responsive cases (stage 3), often combined with platelet-rich fibrin or laser therapy [7][16].

  • Preventive: Pre-therapy dental evaluation, minimally invasive procedures (e.g., root canals over extractions), and smoking cessation [1][5][9].

Categories: rare bone diseases, rare systemic and rheumatological diseases

Research Papers

2,073 drug discovery papers about Osteonecrosis of the jaw, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

2,073 drug discovery papers about Osteonecrosis of the jaw, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

antibodies
2026-05-04 | Denosumab Therapy in Dental Practice: Awareness, Risk Factors and Preventive Strategies.

Denosumab is increasingly prescribed for osteoporosis and metastatic bone disease, leading to a parallel rise in reports of medication-related osteonecrosis of the jaw (MRONJ). Although the condition was first associated with bisphosphonate therapy, emerging evidence indicates that denosumab-associated MRONJ presents distinct epidemiological, clinical and management challenges. Despite an expanding body of research, awareness of MRONJ risk among general dental practitioners remains inconsistent, contributing to preventable adverse outcomes. This narrative review consolidates current knowledge on MRONJ in denosumab-treated patients by examining epidemiology, pathophysiology, clinical features, established risk factors and evidence-based preventive strategies. Numerous guidelines consistently emphasise early dental assessment, optimisation of oral health prior to the first denosumab dose and timely communication between physicians and dental clinicians. A planned dental intervention may be safer when coordinated around the denosumab dosing schedule, particularly by utilising a "window of opportunity" during periods of the waning drug effect. This review also synthesises practical recommendations for routine dental care, pretreatment evaluation, risk stratification and management of established MRONJ. A clinical decision-making flowchart is proposed to assist dental practitioners in evaluating treatment needs, assessing patient risk and planning interventions with minimal disruption to systemic therapy. Taken together, understanding the unique characteristics of denosumab-associated MRONJ is essential for reducing morbidity and improving patient outcomes. Strengthening collaboration between dental practitioners and medical prescribers, along with early identification of vulnerable patients, remains the cornerstone of prevention.

Open article ↗



2026-04-09 | The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.

Rare bone diseases may display a disrupted RANKL-RANK-Osteoprotegerin pathway causing increased osteoclastogenesis and enhanced bone resorption. Although bisphosphonates are commonly used, they often fall short of desired outcomes. Denosumab, an anti-RANKL antibody, provides a promising alternative by swiftly and strongly suppressing bone turnover (faster and more potent suppression of bone resorption than bisphosphonates), though its effects are reversible upon discontinuation. The use of denosumab has been highlighted, especially in pediatric cases but not substantially in adults. A targeted evidence search was conducted to retrieve studies reporting denosumab use in rare bone diseases in adults. Denosumab administration may lead to pain reduction, lesion reduction or bone formation. Treatment dosage, schedules and duration varied, however, a dose of 120 mg dosed monthly or 3 monthly for almost one year reached the desired treatment effect in most patients. Denosumab is generally well tolerated in adults, with mild common side effects such as (asymptomatic) hypocalcemia and hypophosphatemia. Serious adverse effects such as osteonecrosis of the jaw or atypical femoral fractures are rarely reported. Main concerns regard rebound effect after denosumab discontinuation, with disease recurrence in some cases. Zoledronic acid after discontinuation of denosumab might be advisable, but is seldom reported. Denosumab is a feasible treatment in adults with rare bone diseases when managed by multidisciplinary teams with knowledge of both the underlying disease and potential surgeries as well as the medical site of treatment. Denosumab discontinuation management is paramount to prevent recurrence and severe complications. The paucity of data supports the need for data collection through rare disease registries for future pertinent evidence-based recommendations.

Open article ↗



2026-04-06 | Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw.

This study aimed to assess the occurrence of medication-related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro. Thirty-five female C57BL/6 mice were divided into three groups: romosozumab followed by zoledronate (ROM+ ZOL), saline followed by zoledronate (ZOL), and control (Con) group receiving saline. After drug administration, the maxillary first molars were extracted. Bone healing and necrosis were evaluated using micro-computed tomography, histomorphometry, and immunohistochemistry. To investigate the mechanism underlying the in vivo study results, the effects of romosozumab and zoledronate were evaluated by analysing tartrate-resistant acid phosphatase staining and actin ring formation after differentiation of RAW 264.7 cells. The ROM+ZOL group exhibited more severe bone necrosis than the ZOL and Con groups. The ROM+ZOL group demonstrated a lower bone volume fraction and a reduction in the number of sclerostin-positive cells, suggesting enhanced osteonecrosis when romosozumab was administered before zoledronate. Moreover, both zoledronate and romosozumab effectively suppressed osteoclast differentiation and function in vitro. Sequential administration of romosozumab followed by zoledronate may exacerbate the risk of MRONJ, underscoring the need for careful consideration in clinical applications.

Open article ↗



2026-03-12 | Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report.

Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) are rare but serious complications associated with long-term use of antiresorptive therapies such as denosumab. Denosumab discontinuation to allow for bone healing is not possible because of the high risk of spontaneous multiple vertebral fractures. We present a case of concurrent AFF and ONJ in a patient previously treated with denosumab 120mg monthly. The patient was managed with a low-dose denosumab regimen tailored according to bone turnover marker monitoring, resulting in successful bone union and resolution of ONJ.

Open article ↗



2026-02-27 | Clinical characteristics of osteonecrosis of the jaw related to denosumab: a 5-year retrospective cohort study.

This study aimed to investigate the clinical characteristics, treatment outcomes, and factors influencing treatment success in patients with denosumab (Dmab)-related osteonecrosis of the jaw (DRONJ). This retrospective cohort study included the patients who were diagnosed with DRONJ and treated at the authors' affiliated hospital, between August 2019 and August 2024. The patients were divided into the three groups; Group 1, low-dose Dmab; Group 2, transition from bisphosphonates (BPs) to low-dose Dmab; Group 3, high-dose Dmab. Differences in clinical characteristics among the groups were compared. Surgical outcomes were classified into three categories: complete healing, partial healing, and no healing. "Treatment success" was defined as the combined proportion of complete and partial healing. A total of 178 DRONJ patients were included in this study. Most of DRONJ occurred in osteoporosis patients. In patients treated with lowdose Dmab, prior BP use resulted in the development of MRONJ within a shorter period after Dmab administration but did not affect disease severity or treatment outcomes. Overall postoperative healing outcomes were favorable at 3 months after DRONJ treatment. The overall treatment success rate was 81.5%; Group 1, 85.0%; Group 2, 82.8%; Group 3, 53.8%, P=0.027). Multiple regression analysis demonstrated that Dmab dosage was a significant factor influencing treatment success, whereas age, treatment duration, lesion location, and DRONJ stage were not (odds ratio, 5.13; 95% confidence interval, 1.19-22.14; P=0.028). The earlier onset in the BP to Dmab transition group may be attributable to the cumulative duration of antiresorptive therapy. Patients treated with high-dose Dmab demonstrated poorer prognosis and more frequent recurrence after MRONJ treatment compared with those treated with low-dose Dmab or BP to Dmab transition therapy. herefore, these findings need to be considered for treatment of DRONJ.

Open article ↗



small molecules
2026-09-17 | Artificial Intelligence-Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions.

Bisphosphonates remain the pharmacological standard of care for osteoporosis; however, their clinical efficacy is limited by significant diagnostic gaps, heterogeneous therapeutic responses, and persistent concerns regarding long-term safety, including medication-related osteonecrosis of the jaw (MRONJ) and atypical femoral fractures (AFF). To address these limitations, a structured comprehensive search of the Web of Science Core Collection, Scopus, and PubMed (January 2005-December 2025) was conducted to evaluate the intersection of bisphosphonate pharmacotherapy and computational medicine. The integration of artificial intelligence (AI) facilitates a methodological transition from empirical prescription to precision medicine across critical clinical domains. (1) Screening and Diagnosis: AI-driven opportunistic screening utilizes routine computed tomography (CT) scans to automate asymptomatic vertebral fracture detection and assess bone quality via radiomics. (2) Treatment Stratification: Machine learning algorithms enable the prediction of individual bone mineral density (BMD) responses and optimize alternative or sequential therapies, facilitating precise patient selection for potent agents like zoledronic acid. (3) Safety Monitoring: Predictive models integrating clinical and imaging data allow for the pre-emptive risk stratification of adverse events, shifting management from passive surveillance to active prevention. (4) Smart Delivery Systems: Furthermore, computational modeling accelerates the design of stimuli-responsive nanocarriers to improve bone targeting and reduce systemic toxicity. Despite current challenges regarding algorithmic interpretability and multi-center validation, incorporating emerging technologies-such as large language models (LLMs) for clinical triage and the integration of systemic metabolic networks (e.g., the gut-bone axis)-suggests a promising trend toward a data-informed, risk-adjusted, and biologically targeted precision ecosystem in osteoporosis management.

Open article ↗



2026-09-15 | How to Prepare Patients Receiving Antiresorptive Therapy for Tooth Extraction: A Narrative Review.

Bisphosphonates (BPs) and Denosumab (DMB) are antiresorptive agents (AA) commonly used in treatment of osteoporosis, multiple myeloma (8.0%), breast cancer (3.3%), prostate cancer (2.9%) and other malignancies (0.7%), bone metastases, and cancer-induced hypercalcemia. However, this therapy is associated with a significant risk of medication-related osteonecrosis of the jaw (MRONJ), particularly after tooth extraction. The aim of this narrative review was to summarize current evidence on measures aimed to reduce the risk of MRONJ after tooth extraction, and to critically discuss the strength of evidence supporting each of these measures. Articles published in the years 2013-2025 were reviewed using PubMed, Scopus, Web of Science databases. Available studies were categorized and compared with the use of selected prevention methods. The duration of the treatment, route of administration, dosage and type of AA have a significant impact on the risk of developing MRONJ. Antibiotic prophylaxis is considered in most published preventive protocols. However, the evidence supporting a single optimal regimen is limited. Patients from a high-risk group of MRONJ, demonstrating cancer, who were administered intravenous antiresorptive agents for longer than three years or zoledronic acid, or those with a history of jawbone necrosis or inflammation require prolonged antibiotic therapy (started before the procedure and continued up to 14 days after the procedure). Moreover, studies on the use of platelet-rich fibrin (PRF) and Concentrated Growth Factors (CGF) as a preventive measure have shown promising results in observational studies, along with antibiotic prophylaxis and optimal oral hygiene. Pentoxifylline with tocopherol and low-level laser therapy (LLLT) are recognized as potentially useful non-invasive preventions. However, evidence is limited due to the small sample sizes and heterogenous protocols. Vitamin D levels should be monitored, and oral supplementation should be considered if needed. AA therapy suspension prior to the surgical procedure must always be consulted with the attending physician. A multidisciplinary approach along with well-planned pre- and postoperative care is essential for safe tooth extraction in patients receiving AA therapy.

Open article ↗



2026-09-07 | Osteonecrosis of the jaws beyond antiresorptive drugs and radiotherapy: a scoping review of uncommon etiologies, pathogenetic mechanisms and clinical management.

Osteonecrosis of the jaw is most commonly discussed in relation to antiresorptive or antiangiogenic medications and head and neck radiotherapy. However, a heterogeneous group of jaw osteonecrosis cases occurs in the absence of these recognized triggers and remains poorly systematized. This review summarizes the current evidence on jaw osteonecrosis occurring outside the classical settings of antiresorptive/antiangiogenic medication exposure and head and neck radiotherapy, with the aim of clarifying its etiological spectrum, clinical presentation, diagnostic challenges, and management principles. The available literature is largely composed of case reports, small case series, and retrospective studies, reflecting the rarity and heterogeneity of these conditions. Reported causes include local traumatic or idiopathic oral ulceration with bone sequestration, viral infections, immunosuppression, chemotherapy, hematological malignancies, hematopoietic stem cell transplantation, hemoglobinopathies, metabolic or genetic bone disorders, vascular and thrombotic abnormalities, and toxic or recreational drug exposure. Clinical manifestations range from small, self-limited sequestra over bony prominences to extensive necrosis with tooth exfoliation, fistulae, infection, pathological fracture, and midfacial involvement. Management should be tailored to the underlying cause and disease extent, ranging from conservative sequestrectomy to radical debridement or resection combined with systemic treatment. Recognition of these entities is essential to avoid misdiagnosis and to guide appropriate multidisciplinary care.

Open article ↗



2026-09-03 | Fluvastatin enhances healing of medication-related osteonecrosis of the jaw (MRONJ) via macrophage polarization in a rat MRONJ-like model.

Medication-related osteonecrosis of the jaw (MRONJ), a serious adverse effect of antiresorptive agents, remains difficult to manage. Our previous studies showed that statins, widely prescribed for dyslipidemia, promote healing in MRONJ-like lesions, however, the mechanisms underlying their therapeutic effects remain unclear. This study investigated the efficacy of the therapeutic effect of fluvastatin (FS) in a rat MRONJ-like model, with particular attention to macrophage polarization. Four-week-old female rats were allocated to three groups. Two groups received zoledronic acid (ZOL) and dexamethasone (DEX) for two weeks prior to extraction of maxillary first molars. After extraction, one group was treated with a single local injection of FS near the extraction site, whereas the other received saline. A control group underwent identical procedures, but received saline instead of ZOL, DEX, and FS. All animals were evaluated two weeks after treatment. The control (saline) group showed complete socket healing. In contrast, ZOL/DEX-treated rats exhibited incomplete epithelial closure and exposed necrotic bone. However, local FS administration in ZOL/DEX-treated rats extensively promoted healing, resulting in smaller epithelial gaps and reduced bone exposure, and decreased areas of necrotic bone. Total macrophage numbers were significantly higher in both experimental groups compared with the control group. The ZOL/DEX group showed a predominance of pro-inflammatory M1 macrophages, whereas the FS-treated group exhibited relatively increased proportions of tissue-reparative M2 macrophages. Local FS administration enhances bone healing of MRONJ-like lesions by promoting macrophage polarization toward M2 phenotype.

Open article ↗



2026-08-29 | Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ.

Sunitinib is a widely used multi-target tyrosine kinase inhibitor associated with side effects that may impair tissue repair and regeneration, potentially contributing to the onset of medication-related osteonecrosis of the jaw. Macrophages play a central role in tissue homeostasis and regeneration, and their dysfunction may be a key factor in this pathological process. In this study, a zebrafish tail fin injury regeneration model was used to investigate the effects of sunitinib on macrophage function and tissue regeneration. Transcriptomic analysis, immunofluorescence staining, RT-qPCR, and Seahorse mitochondrial stress assays were performed to elucidate the underlying mechanisms. Sunitinib treatment significantly impaired macrophage migration and tissue regeneration in a concentration-dependent manner. Transcriptomic analysis revealed that sunitinib markedly suppressed the PPARγ signaling pathway, reparative gene programs, and mitochondrial metabolism. The density of PPARγ+ macrophages at the wound site was significantly reduced following sunitinib exposure. Treatment with rosiglitazone, a PPARγ agonist, effectively rescued the regeneration defects induced by sunitinib, restored macrophage infiltration, and recovered oxidative phosphorylation. Notably, these rescuing effects were abolished upon macrophage depletion. Our results demonstrate that sunitinib impairs tissue regeneration by suppressing PPARγ signaling and oxidative phosphorylation in macrophages. Targeting the PPARγ pathway represents a promising therapeutic strategy to reverse sunitinib-associated deficits in tissue repair.

Open article ↗



proteins
2026-09-03 | Efficacy of concentrated growth factors preventing medication-related osteonecrosis of the jaw following tooth extraction in patients on intravenous bisphosphonates: A randomized controlled trial.

Medication-related osteonecrosis of the jaw (MRONJ) constitutes a severe postoperative complication following tooth extraction in patients with intravenous bisphosphonates (BPs) exposure. This study aimed to evaluate concentrated growth factors (CGF) in preventing MRONJ and enhancing tissue healing after tooth extraction in intravenous BPs treated patients. This randomized controlled trial enrolled 119 patients (150 extraction sites). Extraction sites were randomly allocated to minimally invasive extraction alone (control, N = 75) or with CGF (test, N = 75). MRONJ incidence was assessed at least 8 weeks postoperatively. Gingival buccolingual width and fissure area were measured immediately after extraction and at 1, 2, and 4 weeks postoperatively. In the total cohort and the intravenous BPs combined with denosumab cohort, the incidence of MRONJ in the test group was significantly lower than that in the control group (P =0.028 and P=0.022, respectively). The test group showed significantly greater reduction in postoperative gingival buccolingual width at 1, 2 and 4 weeks and gingival fissure area at 1 and 2 weeks compared to controls (P < 0.05). MRONJ patients had greater intravenous BPs injection times than those without MRONJ (P < 0.001). Minimally invasive tooth extraction with CGF may effectively reduce the risk of MRONJ and promote tissue healing in patients treated with intravenous BPs, particularly those receiving concomitant denosumab therapy.

Open article ↗



2026-08-19 | Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw.

Medication-related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive and antiangiogenic therapies. Prolonged suppression of bone remodeling has been implicated as a key mechanism in its pathophysiology. Teriparatide, an osteoanabolic agent that restores coupled bone remodeling, has been proposed as a potential therapeutic strategy. This review aimed to synthesize reported clinical outcomes of teriparatide use in MRONJ within a systemic remodeling-based framework. We conducted a structured descriptive review based on a systematic literature search and reported in accordance with PRISMA 2020. Studies reporting therapeutic use of teriparatide in established MRONJ were included regardless of the triggering medication. Data were extracted on patient characteristics, MRONJ stage, lesion site, antiresorptive exposure, teriparatide regimen, antiresorptive interruption, antiresorptive type, and clinical outcomes. Because of substantial heterogeneity in study design, patient populations, co-interventions, and outcome reporting, evidence was synthesized qualitatively. Thirty-four publications including 207 patients were included. Clinical outcomes were available for 201 patients: complete coverage/healing was reported in 163, partial improvement in 24, no change in 12, and worsening in 2. Teriparatide discontinuation or dropout after treatment initiation was reported in 13 patients. Stage 2 disease predominated among stageable cases, mandibular involvement was the most frequent anatomical site, and daily teriparatide dosing was more commonly reported than weekly regimens. Bisphosphonate exposure predominated, whereas denosumab-associated cases were fewer; therefore, differential effectiveness by antiresorptive class could not be determined. Published reports describe frequent clinical improvement after teriparatide use in MRONJ. However, the evidence remains descriptive, heterogeneous, and commonly confounded by concomitant therapies. These findings support a biologically plausible remodeling-based interpretation but do not establish efficacy or define teriparatide as standard therapy.

Open article ↗



2026-07-29 | Should Teriparatide Be Part of Our Clinical Armamentarium in the Management of Medication-Related Osteonecrosis of the Jaw? A Systematic Review and Meta-Analysis.

Medication-related osteonecrosis of the jaw (MRONJ) is a severe and potentially debilitating drug reaction. Adjunctive treatments including pentoxifylline, tocopherol, and teriparatide (TPTD) have been studied, but TPTD's efficacy remains unclear. This systematic review and meta-analysis aims to consolidate and evaluate high-quality evidence on TPTD in managing MRONJ. An electronic search strategy was performed on 3 databases (Pubmed, Embase, and Cochrane CENTRAL). Search terms include ("Teriparatide" OR "TPTD" OR "Recombinant Parathyroid Hormone" OR "Recombinant PTH") AND ("Medication-Related Osteonecrosis of the Jaw" OR "MRONJ" OR "BRONJ"). No publication date range was utilized. Inclusion criteria include randomized controlled trials, case-control studies, and cohort studies. All systematic reviews, case reports, case series, animal studies, editorials, non-English publications, or studies relating to osteoradionecrosis were excluded. Each study was screened independently, followed by final study selection after discussion with all authors. Primary meta-analysis used Cox proportional hazards regression with pseudo-individual-subject data reconstructed from published Kaplan-Meier curves (Guyot method) and a Tierney events + P value derivation for one study without Kaplan-Meier data. A sensitivity analysis pooled odds ratios (ORs) at the 6-month clinical response endpoint. Primary outcomes include improvement in MRONJ clinical staging. Secondary outcomes include time to improvement, adverse effects, radiographic evaluation, and presence of serum markers. After review of 162 studies, 5 (3.1%) studies were included in the systematic review with 3 (1.9%) studies included in the meta-analysis (n = 101 subjects). A three-study Cox hazard ratio (HR) meta-analysis yielded a pooled HR of 5.35 (95% CI, 3.14 to 9.13, P < .0001, I2 = 0%) favoring TPTD. Subgroup analyses by dosing regimen showed directionally consistent effects (daily pooled HR = 12.52; 95% CI, 5.75 to 27.23; weekly pooled HR = 8.09; 95% CI, 3.59 to 18.26; both I2 = 0%), and an OR-based sensitivity analysis at the 6-month binary healing endpoint was directionally concordant (pooled OR = 14.26; 95% CI, 2.83 to 71.77). Adjunctive TPTD shows improvement of MRONJ staging and time to healing compared to conventional treatments alone, but the magnitude of the impact remains unclear. Additional evidence, including studies evaluating dosing regimens and subject segmentation by MRONJ staging, is warranted.

Open article ↗



2026-07-11 | Pharmacological and surgical predictors of postoperative healing in medication-related osteonecrosis of the jaw: A retrospective multicenter cohort study.

Failure to achieve postoperative healing after surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) remains a clinical challenge. We aimed to investigate the independent predictors of postoperative nonhealing and to evaluate the impact of regenerative adjuncts. In a multicenter surgical cohort (2019-2025) of 531 patients with MRONJ, pharmacological, lesion level, and surgical factors were assessed using univariable testing, elastic net regularization for variable selection, and multivariable logistic regression. Postoperative nonhealing was defined as the need for additional surgical intervention or failure to achieve complete mucosal coverage, accompanied by clinical or radiographic evidence of persistent or progressive disease. Kaplan-Meier analysis was used to estimate nonhealing-free survival. The overall postoperative nonhealing rate was 18.5% (98/531). In the multivariable models, high-dose antiresorptive therapy (odds ratio [OR]: 2.94, 95% confidence interval [CI]: 1.70-5.06) and multiple-site lesions (OR: 2.29, 95% CI: 1.09-4.67) were independent risk factors for postoperative nonhealing, whereas intraoperative bone morphogenetic protein (BMP) use was associated with a lower risk of postoperative nonhealing (OR: 0.32, 95% CI: 0.20-0.52). The number needed to treat to prevent one postoperative nonhealing event was 5.3 (95% CI: 3.9-8.7) for BMP, and the number needed to harm was 4.4 (95% CI: 3.0-8.5) for high-dose therapy. Solitary maxillary lesions showed an insignificant protective effect. Antiangiogenic agents were associated with postoperative nonhealing in the univariate and elastic net analyses, but not in the final multivariable model. Neither treatment duration nor preoperative drug holiday was independently associated with postoperative nonhealing. The elastic net model showed acceptable discrimination (area under the curve [AUC]: 0.724), and the Kaplan-Meier curves were consistent with these findings. Postoperative nonhealing after surgical management of MRONJ was mainly associated with systemic pharmacological burden and lesion extent, whereas BMP application was associated with improved postoperative healing. These findings support further investigation of regenerative adjuncts and risk-adapted surgical management strategies.

Open article ↗



2026-05-22 | Synergistic application of concentrated growth factor and bone perforation technique in bisphosphonate-related-osteonecrosis of the jaw.

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication caused by the deposition of bisphosphonates in bone tissue, particularly after invasive dental procedures. Its pathogenesis is closely related to impaired bone remodeling and insufficient blood supply. Optimizing treatment strategies for BRONJ remains a significant clinical challenge. This study aims to evaluate the therapeutic effects of concentrated growth factor (CGF) combined with the bone perforation technique in the treatment of BRONJ. A rat model of BRONJ was established and divided into four groups: Non-treated group (N), Bone perforation group (B), CGF group (C), and CGF + Bone perforation group (C + B). Bone repair was evaluated at 2 and 4 weeks post-treatment through micro-computed tomography (Micro-CT), histological analysis (HE and TRAP staining), Western blot, immunofluorescence staining, and qRT-PCR (RUNX2, ALP). HE staining at 2 weeks postoperatively showed abundant empty lacunae with inflammation in the N and B groups, while the C and C + B groups exhibited reduced necrotic bone and new bone formation. At 4 weeks, the C + B group achieved complete epithelial healing with no residual necrotic bone. Quantitative histomorphometry revealed that the TRAP-positive area was 0.32% in the C group and 0.27% in C + B groups, significantly higher than that in the N group 0.12%(p < 0.001). PCR analyses revealed that, at 2 weeks, ALP expression was highest in the C group compared to all other groups (N, B, and C + B) (p < 0.001), whereas RUNX2 expression showed no significant difference between the C and C + B groups but was significantly higher than that in the N and B groups (p < 0.01). At 4 weeks, the C + B group exhibited the highest ALP and RUNX2 expression, significantly exceeding all other groups (N, B, and C). Western blot analyses demonstrated that at 2 weeks post-surgery, ALP and RUNX2 protein expression was higher in the C group than in all other groups (p < 0.05). At 4 weeks, ALP expression was higher in the C and C + B groups compared to the other groups (p < 0.001). RUNX2 expression was highest in the C + B group (p < 0.001). Our results demonstrate that CGF significantly promotes BRONJ repair, while the bone perforation technique improves early blood supply but has limited long-term therapeutic effects. The combined application of CGF and bone perforation exerts a synergistic effect in enhancing osteogenesis and optimizing bone repair outcomes. Future studies with larger sample sizes and longer follow-up periods are warranted to verify these findings.

Open article ↗



cell therapies
2026-08-09 | Individualized 3D-Printed Titanium Mesh-Assisted Alveolar Reconstruction and Implant Rehabilitation Following MRONJ Resection: A Case Report.

Medication-related osteonecrosis of the jaw is a severe complication of antiresorptive therapy that often necessitates complex reconstructive surgery. This report describes a case of implant-supported rehabilitation using a customized 3D-printed titanium mesh for an extensive mandibular defect resulting from medication-related osteonecrosis of the jaw. A 58-year-old woman with stage-3 medication-related osteonecrosis of the jaw after zoledronate therapy underwent segmental mandibulectomy and reconstruction with a free iliac crest graft. Nine months later, a customized titanium mesh was placed to protect the planned 9.5-11 mm augmentation. Cone beam computed tomography confirmed mineralized regeneration within the mesh. The mesh was removed after achieving 9.5 mm vertical and 11 mm horizontal alveolar augmentation, and 4 implants were placed with high primary stability (insertion torque ≥ 40 N cm). At 6 months, resonance frequency analysis values ranged from 75 to 84, allowing delivery of a splinted fixed prosthesis. At 12 months of loading, the peri-implant tissues remained normal with stable radiographic bone levels and satisfactory function. Combining customized 3D-printed titanium mesh with guided implant placement supports stable bone regeneration and prosthetic rehabilitation in patients with medication-related osteonecrosis of the jaw. However, outcomes depend on medication history, therapy timing, and unresolved drug-related factors, underscoring the need for a multidisciplinary approach with individualized treatment and proactive complication care.

Open article ↗



2026-07-31 | [A retrospective study of pedicled flaps for repair of oral mucosal defects in patients with medication-related osteonecrosis of the jaw].

Objective: To investigate the clinical efficacy of pedicled flaps for repairing oral mucosa defects in medication-related osteonecrosis of the jaw (MRONJ), and to analyze the indications for different types of pedicled flaps. Methods: The clinical data of 158 MRONJ patients who met the inclusion criteria and were admitted to the Department of Maxillofacial Trauma and Orthognathic Surgery, Hospital of Stomatology, Air Force Medical University from January 2019 to December 2024 were retrospectively analyzed, including 74 males (46.8%) and 84 females (53.2%).The mean age was (59.2±10.7) years (range, from 20 to 87 years old). According to the method of soft tissue repair, the patients were divided into direct suture group (61 cases) and pedicled tissue flap group (97 cases, including 80 cases of buccal fat pad flap and 17 cases of submental island flap). The rate of secondary operation was compared between the two groups. Multivariate binary Logistic regression and subgroup analysis were used to evaluate the efficacy and influencing factors of pedicled tissue flaps, and the comparison between the buccal fat pad flap and submental island flap was performed. Results: The median follow-up time was 36 months. Univariate analysis showed that the secondary operation rate was 68.9% (42/61) in the direct suture group, which was significantly higher than 16.5% (16/97) in the pedicled tissue flap group (P<0.001). After adjusting for confounding factors such as age and lesion location, multivariate Logistic regression analysis showed that pedicled tissue flap was an independent protective factor against the risk of secondary surgery (OR=0.049, P<0.001). Stage 3 disease was an independent risk factor for secondary surgery (OR=8.455, P=0.002). Subgroup analysis showed that the secondary operation rate of pedicled tissue flap was significantly lower than that of direct suture in stage 3 group, mandibular group,<65 years group, male group and female group (all P<0.05). There was no significant difference among stage 2 group, maxillary group and≥65 years group (all P>0.05), but the trend of protection was the same. The secondary operation rate was 17.5% (14/80) in the buccal fat pad flap group and 2/17 in the submental island flap group. There was no significant difference between the two groups (P=0.730). Conclusions: The use of pedicled tissue flap for repairing oral mucosal wounds can significantly reduce the risk of secondary surgery for MRONJ, and the effect is superior to direct suture. Buccal fat pad flap is the first choice for maxillary and retromolar mucosal defects, and submental island flap can be used for large mandibular mucosal defects.

Open article ↗



2026-07-31 | [Research progress of mesenchymal stem cells in the treatment of medication-related osteonecrosis of the jaw].

Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication characterized primarily by jawbone necrosis, induced by bisphosphonates or other targeted agents for systemic diseases. With the advancement of systemic anticancer therapies, the survival of patients with advanced malignancies has been prolonged, leading to an annual increase in the number of patients with MRONJ. However, there is currently no effective treatment for MRONJ worldwide. Recent studies have indicated that mesenchymal stem cells exhibit significant potential for osteogenic and angiogenic differentiation, proliferation, immunomodulation, and anti-inflammatory effects, thereby providing a novel therapeutic strategy for medication-related osteonecrosis of the jaw. This article reviews the research on mesenchymal stem cell therapy for MRONJ, providing a reference for its clinical research and treatment.

Open article ↗



2026-06-01 | Human Amniotic Membrane as Adjuvant Therapy in Medication-Related Osteonecrosis of the Jaw: A Scoping Review

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication characterized by progressive destruction of the maxillary and mandibular bones in patients receiving antiresorptive or antiangiogenic agents. Despite evolving clinical guidelines, its management remains controversial and nonstandardized. Human amniotic membrane (HAM) has emerged as a promising adjuvant therapy due to its immunomodulatory, anti-inflammatory, and regenerative properties. Objective: To identify and synthesize available evidence on the effectiveness of HAM as an adjuvant treatment in promoting wound healing in patients diagnosed with MRONJ. Methods: A scoping review was conducted following the PRISMA-ScR framework. Searches were performed in PubMed/MEDLINE, Scopus, and Web of Science using MeSH terms and free-text keywords including “amniotic membrane,” “amnion,” “bisphosphonate-associated osteonecrosis,” and “medicationrelated osteonecrosis of the jaw,” combined with Boolean operators. Searches were limited to primary human studies published within the past five years. Results: A total of 25 records were identified; after deduplication and screening, 3 primary studies were included comprising a total of 39 patients across various MRONJ stages. Across all studies, 83.8% of patients achieved complete mucosal wound closure, and 84.6% reported a significant reduction in pain perception. No adverse events, recurrences, or infectious complications were reported. Conclusions: HAM represents a viable, versatile, and effective adjuvant intervention in the surgical management of MRONJ. It promotes soft-tissue healing, reduces pain and infection, and favorably impacts patient prognosis and quality of life. Randomized controlled trials with larger samples and standardized protocols are warranted.

Open article ↗



2026-05-20 | Mesenchymal stem cell therapy for treatment of medication related osteonecrosis of the jaw (MRONJ): A systematic review.

Medication-related osteonecrosis of the jaw (MRONJ) is a significant adverse effect associated with antiresorptive and antiangiogenic therapies. Therapies utilizing mesenchymal stem cells (MSCs) represent a promising regenerative strategy; however, conventional management methods have shown limited effectiveness. This systematic review aimed to evaluate the effectiveness of MSC-based interventions in preventing and treating MRONJ. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science to identify studies published from 2011 to 2024. Studies examining MSCs therapy in the context of MRONJ were incorporated according to predefined inclusion and exclusion criteria. Seventeen studies (6 clinical, 11 preclinical) met inclusion criteria. Preclinical models demonstrated that MSCs enhance angiogenesis and bone regeneration, providing mechanistic support for human application. Clinically, 80-90% of patients achieved complete mucosal healing with radiographic evidence of bone regeneration. However, due to species differences in oral microbiome and immunity, animal findings require confirmation in human trials. This review integrates human clinical data with mechanistic insights from preclinical studies. Human evidence shows promising mucosal and bone regeneration, while animal studies elucidate underlying mechanisms-particularly angiogenesis and immunomodulation. Given that animal models cannot replicate the human oral immune environment, these findings should be interpreted as hypothesis-generating. MSC therapy represents a biologically sound but experimental strategy, warranting confirmation through randomized controlled trials.

Open article ↗



other
2025-12-11 | The Mitigating Effect and Mechanism of Polydeoxyribonucleotide Against Zoledronic Acid-Induced Growth Suppression of Human Gingival Fibroblasts.

Zoledronic acid (ZA), a nitrogen-containing bisphosphonate, is widely used to treat osteoporosis and bone metastases. However, its clinical application is limited by adverse effects, notably bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is associated with cytotoxicity in oral mucosal cells. Polydeoxyribonucleotide (PDRN), a salmon sperm-derived DNA polymer with regenerative and anti-inflammatory properties, has shown therapeutic potential in tissue repair; however, its ability to mitigate ZA-induced cytotoxicity remains poorly understood. Here, we investigated the molecular mechanisms of ZA-induced toxicity in HGF-1 cells, a human gingival fibroblast line, and evaluated the protective effects of PDRN. ZA treatment (50 µM, 48 h) significantly inhibited HGF-1 cell growth, accompanied by reduced phosphorylation of protein kinase B (PKB) and signal transducer and activator of transcription 3 (STAT-3), along with increased phosphorylation of TANK-binding kinase 1 (TBK1). TBK1 silencing restored cell growth under ZA exposure, whereas silencing PKB or STAT-3 further suppressed cell growth even without ZA. Co-treatment with PDRN (100 µg/mL) effectively prevented and reversed ZA-induced HGF-1 cytotoxicity. Mechanistically, PDRN inhibited ZA-induced TBK1 phosphorylation and partially restored PKB phosphorylation, though it did not reverse the reduction in p-STAT-3. Additionally, ZA significantly elevated intracellular reactive oxygen species (ROS) levels at 8 h, which were attenuated by PDRN. The antioxidant N-acetylcysteine (NAC) similarly reduced ZA-induced ROS and p-TBK1 levels and improved cell growth, although it had limited effects on p-PKB at 8 h. Importantly, delayed PDRN treatment following ZA exposure reversed ZA-induced cell growth inhibition and TBK1 activation in a dose- and time-dependent manner. In summary, these findings demonstrate that ZA suppresses HGF-1 cell growth through ROS production, TBK1 activation, and inhibition of PKB and STAT-3, whereas PDRN counteracts these effects primarily by suppressing TBK1 activation and oxidative stress.

Open article ↗



2025-09-02 | Rethinking Osteonecrosis of the Jaw: Could Cellular Senescence Be the Missing Link Between ORN and MRONJ?

Osteonecrosis of the jaw (ONJ) is a series bone diseases characteristic with similar diagnostic criteria and clinical manifestations. Phossy jaws, medication-related osteonecrosis of the jaw (MRONJ), and osteoradionecrosis (ORN) are major subtypes of ONJ. Though subtypes of ONJ are considered different diseases in clinical practice, similar diagnostic criteria, clinical presentation, and features prompt the possibility that there is a common pathogenesis mechanism for ONJ subtypes. Current pathogenic theories fail to fully explain the delayed onset, persistent progression, and stimulus-independent nature of ONJ. Here, we propose that cellular senescence could be a common pathogenesis mechanism of ONJ. Radiation, antiresorptive agents, and trauma induce persistent DNA damage and activate the DNA damage response, leading to irreversible senescence in jawbone cells. This model explains key clinical observations and offers a rationale for the failure of stimulus withdrawal to reverse disease progression. We outline future directions to validate this hypothesis. If confirmed, this hypothesis may unify ONJ subtypes under a single pathogenic framework and open avenues for targeted interventions.

Open article ↗



2024-10-16 | Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare side effect of antiresorptive drugs that significantly hinders the quality of life of affected patients. The disease develops in the presence of a combination of factors. Important pathogenetic factors include inflammation, inhibition of bone remodeling, or genetic predisposition. Since the first description of this rare side effect in 2003, a growing body of data has suggested a possible role for genetic factors in the disease. Several genes have been suggested to play an important role in the pathogenesis of MRONJ such as SIRT1, VEGFA, and CYP2C8. With the development of molecular biology, newer methods such as miRNA and gene expression studies have been introduced in MRONJ, in addition to methods that can examine the base sequence of the DNA. Describing the complex genetic background of MRONJ can help further understand its pathophysiology as well as identify new therapeutic targets to better manage this adverse drug reaction.

Open article ↗



2024-07-09 | Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate.

Zoledronate (ZA) stands as a highly effective antiresorptive agent known to trigger medication-related osteonecrosis of the jaw (MRONJ). Its clinical dosages primarily encompass those used for oncologic and osteoporosis treatments. While inflammation is recognized as a potential disruptor of mucosal healing processes associated with ZA, prior research has overlooked the influence of varying ZA dosages on tissue adaptability. Therefore, a deeper understanding of the specific mechanisms by which inflammation exacerbates ZA-induced MRONJ, particularly when inflammation acts as a risk factor, remains crucial. Cell proliferation and migration of human oral keratinocytes (HOK) was analyzed after treatment with different doses of ZA and/or lipopolysaccharide (LPS) to assess their possible effect on mucosal healing of extraction wounds. Mouse periodontitis models were established using LPS, and histological changes in extraction wounds were observed after the administration of oncologic dose ZA. Hematoxylin and eosin (HE) staining and immunofluorescence were used to evaluate mucosal healing. In vitro, LPS did not exacerbate the effects of osteoporosis therapeutic dose of ZA on the proliferation and migration of HOK cells, while aggravated these with the oncologic dose of ZA treatment by inducing mitochondrial dysfunction and oxidative stress via regulating SIRT1 expression. Furthermore, SIRT1 overexpression can alleviate this process. In vivo, local injection of LPS increased the nonunion of mucous membranes in MRONJ and decreased the expression of SIRT1, PGC-1α, and MnSOD. Inflammation aggravates oncologic dose of ZA-induced mitochondrial dysfunction and oxidative stress via a SIRT1-dependent pathway, enhancing the risk of impaired mucosal healing in MRONJ. Our study implies that inflammation becomes a critical risk factor for MRONJ development at higher ZA concentrations. Elucidating the mechanisms of inflammation as a risk factor for mucosal non-healing in MRONJ could inform the development of SIRT1-targeted therapies.

Open article ↗



2023-11-13 | Exosome-targeted delivery of METTL14 regulates NFATc1 m6A methylation levels to correct osteoclast-induced bone resorption

Abstract Osteoporosis has a profound influence on public health. First-line bisphosphonates often cause osteonecrosis of the jaw meanwhile inhibiting osteoclasts. Therefore, it is important to develop effective treatments. The results of this study showed that the increased level of NFATc1 m6A methylation caused by zoledronic acid (ZOL), with 4249A as the functional site, is highly correlated with the decreased bone resorption of osteoclasts. Upstream, METTL14 regulates osteoclast bone absorption through the methylation functional site of NFATc1. Downstream, YTHDF1 and YTHDF2 show antagonistic effects on the post-transcriptional regulation of NFATc1 after the m6A methylation level is elevated by METTL14. In this study, meRIP-Seq, luciferase reporter assays, meRIP and other methods were used to elucidate the NFATc1 regulatory mechanism of osteoclasts from the perspective of RNA methylation. In addition, EphA2 overexpression on exosomes is an effective biological method for targeted delivery of METTL14 into osteoclasts. Importantly, this study shows that METTL14 released by exosomes can increase the m6A methylation level of NFATc1 to inhibit osteoclasts, help postmenopausal osteoporosis patients preserve bone mass, and avoid triggering osteonecrosis of the jaw, thus becoming a new bioactive molecule for the treatment of osteoporosis.

Open article ↗



antibodies
2026-05-04 | Denosumab Therapy in Dental Practice: Awareness, Risk Factors and Preventive Strategies.

Denosumab is increasingly prescribed for osteoporosis and metastatic bone disease, leading to a parallel rise in reports of medication-related osteonecrosis of the jaw (MRONJ). Although the condition was first associated with bisphosphonate therapy, emerging evidence indicates that denosumab-associated MRONJ presents distinct epidemiological, clinical and management challenges. Despite an expanding body of research, awareness of MRONJ risk among general dental practitioners remains inconsistent, contributing to preventable adverse outcomes. This narrative review consolidates current knowledge on MRONJ in denosumab-treated patients by examining epidemiology, pathophysiology, clinical features, established risk factors and evidence-based preventive strategies. Numerous guidelines consistently emphasise early dental assessment, optimisation of oral health prior to the first denosumab dose and timely communication between physicians and dental clinicians. A planned dental intervention may be safer when coordinated around the denosumab dosing schedule, particularly by utilising a "window of opportunity" during periods of the waning drug effect. This review also synthesises practical recommendations for routine dental care, pretreatment evaluation, risk stratification and management of established MRONJ. A clinical decision-making flowchart is proposed to assist dental practitioners in evaluating treatment needs, assessing patient risk and planning interventions with minimal disruption to systemic therapy. Taken together, understanding the unique characteristics of denosumab-associated MRONJ is essential for reducing morbidity and improving patient outcomes. Strengthening collaboration between dental practitioners and medical prescribers, along with early identification of vulnerable patients, remains the cornerstone of prevention.

Open article ↗



2026-04-09 | The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.

Rare bone diseases may display a disrupted RANKL-RANK-Osteoprotegerin pathway causing increased osteoclastogenesis and enhanced bone resorption. Although bisphosphonates are commonly used, they often fall short of desired outcomes. Denosumab, an anti-RANKL antibody, provides a promising alternative by swiftly and strongly suppressing bone turnover (faster and more potent suppression of bone resorption than bisphosphonates), though its effects are reversible upon discontinuation. The use of denosumab has been highlighted, especially in pediatric cases but not substantially in adults. A targeted evidence search was conducted to retrieve studies reporting denosumab use in rare bone diseases in adults. Denosumab administration may lead to pain reduction, lesion reduction or bone formation. Treatment dosage, schedules and duration varied, however, a dose of 120 mg dosed monthly or 3 monthly for almost one year reached the desired treatment effect in most patients. Denosumab is generally well tolerated in adults, with mild common side effects such as (asymptomatic) hypocalcemia and hypophosphatemia. Serious adverse effects such as osteonecrosis of the jaw or atypical femoral fractures are rarely reported. Main concerns regard rebound effect after denosumab discontinuation, with disease recurrence in some cases. Zoledronic acid after discontinuation of denosumab might be advisable, but is seldom reported. Denosumab is a feasible treatment in adults with rare bone diseases when managed by multidisciplinary teams with knowledge of both the underlying disease and potential surgeries as well as the medical site of treatment. Denosumab discontinuation management is paramount to prevent recurrence and severe complications. The paucity of data supports the need for data collection through rare disease registries for future pertinent evidence-based recommendations.

Open article ↗



2026-04-06 | Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw.

This study aimed to assess the occurrence of medication-related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro. Thirty-five female C57BL/6 mice were divided into three groups: romosozumab followed by zoledronate (ROM+ ZOL), saline followed by zoledronate (ZOL), and control (Con) group receiving saline. After drug administration, the maxillary first molars were extracted. Bone healing and necrosis were evaluated using micro-computed tomography, histomorphometry, and immunohistochemistry. To investigate the mechanism underlying the in vivo study results, the effects of romosozumab and zoledronate were evaluated by analysing tartrate-resistant acid phosphatase staining and actin ring formation after differentiation of RAW 264.7 cells. The ROM+ZOL group exhibited more severe bone necrosis than the ZOL and Con groups. The ROM+ZOL group demonstrated a lower bone volume fraction and a reduction in the number of sclerostin-positive cells, suggesting enhanced osteonecrosis when romosozumab was administered before zoledronate. Moreover, both zoledronate and romosozumab effectively suppressed osteoclast differentiation and function in vitro. Sequential administration of romosozumab followed by zoledronate may exacerbate the risk of MRONJ, underscoring the need for careful consideration in clinical applications.

Open article ↗



2026-03-12 | Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report.

Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) are rare but serious complications associated with long-term use of antiresorptive therapies such as denosumab. Denosumab discontinuation to allow for bone healing is not possible because of the high risk of spontaneous multiple vertebral fractures. We present a case of concurrent AFF and ONJ in a patient previously treated with denosumab 120mg monthly. The patient was managed with a low-dose denosumab regimen tailored according to bone turnover marker monitoring, resulting in successful bone union and resolution of ONJ.

Open article ↗



2026-02-27 | Clinical characteristics of osteonecrosis of the jaw related to denosumab: a 5-year retrospective cohort study.

This study aimed to investigate the clinical characteristics, treatment outcomes, and factors influencing treatment success in patients with denosumab (Dmab)-related osteonecrosis of the jaw (DRONJ). This retrospective cohort study included the patients who were diagnosed with DRONJ and treated at the authors' affiliated hospital, between August 2019 and August 2024. The patients were divided into the three groups; Group 1, low-dose Dmab; Group 2, transition from bisphosphonates (BPs) to low-dose Dmab; Group 3, high-dose Dmab. Differences in clinical characteristics among the groups were compared. Surgical outcomes were classified into three categories: complete healing, partial healing, and no healing. "Treatment success" was defined as the combined proportion of complete and partial healing. A total of 178 DRONJ patients were included in this study. Most of DRONJ occurred in osteoporosis patients. In patients treated with lowdose Dmab, prior BP use resulted in the development of MRONJ within a shorter period after Dmab administration but did not affect disease severity or treatment outcomes. Overall postoperative healing outcomes were favorable at 3 months after DRONJ treatment. The overall treatment success rate was 81.5%; Group 1, 85.0%; Group 2, 82.8%; Group 3, 53.8%, P=0.027). Multiple regression analysis demonstrated that Dmab dosage was a significant factor influencing treatment success, whereas age, treatment duration, lesion location, and DRONJ stage were not (odds ratio, 5.13; 95% confidence interval, 1.19-22.14; P=0.028). The earlier onset in the BP to Dmab transition group may be attributable to the cumulative duration of antiresorptive therapy. Patients treated with high-dose Dmab demonstrated poorer prognosis and more frequent recurrence after MRONJ treatment compared with those treated with low-dose Dmab or BP to Dmab transition therapy. herefore, these findings need to be considered for treatment of DRONJ.

Open article ↗



small molecules
2026-09-17 | Artificial Intelligence-Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions.

Bisphosphonates remain the pharmacological standard of care for osteoporosis; however, their clinical efficacy is limited by significant diagnostic gaps, heterogeneous therapeutic responses, and persistent concerns regarding long-term safety, including medication-related osteonecrosis of the jaw (MRONJ) and atypical femoral fractures (AFF). To address these limitations, a structured comprehensive search of the Web of Science Core Collection, Scopus, and PubMed (January 2005-December 2025) was conducted to evaluate the intersection of bisphosphonate pharmacotherapy and computational medicine. The integration of artificial intelligence (AI) facilitates a methodological transition from empirical prescription to precision medicine across critical clinical domains. (1) Screening and Diagnosis: AI-driven opportunistic screening utilizes routine computed tomography (CT) scans to automate asymptomatic vertebral fracture detection and assess bone quality via radiomics. (2) Treatment Stratification: Machine learning algorithms enable the prediction of individual bone mineral density (BMD) responses and optimize alternative or sequential therapies, facilitating precise patient selection for potent agents like zoledronic acid. (3) Safety Monitoring: Predictive models integrating clinical and imaging data allow for the pre-emptive risk stratification of adverse events, shifting management from passive surveillance to active prevention. (4) Smart Delivery Systems: Furthermore, computational modeling accelerates the design of stimuli-responsive nanocarriers to improve bone targeting and reduce systemic toxicity. Despite current challenges regarding algorithmic interpretability and multi-center validation, incorporating emerging technologies-such as large language models (LLMs) for clinical triage and the integration of systemic metabolic networks (e.g., the gut-bone axis)-suggests a promising trend toward a data-informed, risk-adjusted, and biologically targeted precision ecosystem in osteoporosis management.

Open article ↗



2026-09-15 | How to Prepare Patients Receiving Antiresorptive Therapy for Tooth Extraction: A Narrative Review.

Bisphosphonates (BPs) and Denosumab (DMB) are antiresorptive agents (AA) commonly used in treatment of osteoporosis, multiple myeloma (8.0%), breast cancer (3.3%), prostate cancer (2.9%) and other malignancies (0.7%), bone metastases, and cancer-induced hypercalcemia. However, this therapy is associated with a significant risk of medication-related osteonecrosis of the jaw (MRONJ), particularly after tooth extraction. The aim of this narrative review was to summarize current evidence on measures aimed to reduce the risk of MRONJ after tooth extraction, and to critically discuss the strength of evidence supporting each of these measures. Articles published in the years 2013-2025 were reviewed using PubMed, Scopus, Web of Science databases. Available studies were categorized and compared with the use of selected prevention methods. The duration of the treatment, route of administration, dosage and type of AA have a significant impact on the risk of developing MRONJ. Antibiotic prophylaxis is considered in most published preventive protocols. However, the evidence supporting a single optimal regimen is limited. Patients from a high-risk group of MRONJ, demonstrating cancer, who were administered intravenous antiresorptive agents for longer than three years or zoledronic acid, or those with a history of jawbone necrosis or inflammation require prolonged antibiotic therapy (started before the procedure and continued up to 14 days after the procedure). Moreover, studies on the use of platelet-rich fibrin (PRF) and Concentrated Growth Factors (CGF) as a preventive measure have shown promising results in observational studies, along with antibiotic prophylaxis and optimal oral hygiene. Pentoxifylline with tocopherol and low-level laser therapy (LLLT) are recognized as potentially useful non-invasive preventions. However, evidence is limited due to the small sample sizes and heterogenous protocols. Vitamin D levels should be monitored, and oral supplementation should be considered if needed. AA therapy suspension prior to the surgical procedure must always be consulted with the attending physician. A multidisciplinary approach along with well-planned pre- and postoperative care is essential for safe tooth extraction in patients receiving AA therapy.

Open article ↗



2026-09-07 | Osteonecrosis of the jaws beyond antiresorptive drugs and radiotherapy: a scoping review of uncommon etiologies, pathogenetic mechanisms and clinical management.

Osteonecrosis of the jaw is most commonly discussed in relation to antiresorptive or antiangiogenic medications and head and neck radiotherapy. However, a heterogeneous group of jaw osteonecrosis cases occurs in the absence of these recognized triggers and remains poorly systematized. This review summarizes the current evidence on jaw osteonecrosis occurring outside the classical settings of antiresorptive/antiangiogenic medication exposure and head and neck radiotherapy, with the aim of clarifying its etiological spectrum, clinical presentation, diagnostic challenges, and management principles. The available literature is largely composed of case reports, small case series, and retrospective studies, reflecting the rarity and heterogeneity of these conditions. Reported causes include local traumatic or idiopathic oral ulceration with bone sequestration, viral infections, immunosuppression, chemotherapy, hematological malignancies, hematopoietic stem cell transplantation, hemoglobinopathies, metabolic or genetic bone disorders, vascular and thrombotic abnormalities, and toxic or recreational drug exposure. Clinical manifestations range from small, self-limited sequestra over bony prominences to extensive necrosis with tooth exfoliation, fistulae, infection, pathological fracture, and midfacial involvement. Management should be tailored to the underlying cause and disease extent, ranging from conservative sequestrectomy to radical debridement or resection combined with systemic treatment. Recognition of these entities is essential to avoid misdiagnosis and to guide appropriate multidisciplinary care.

Open article ↗



2026-09-03 | Fluvastatin enhances healing of medication-related osteonecrosis of the jaw (MRONJ) via macrophage polarization in a rat MRONJ-like model.

Medication-related osteonecrosis of the jaw (MRONJ), a serious adverse effect of antiresorptive agents, remains difficult to manage. Our previous studies showed that statins, widely prescribed for dyslipidemia, promote healing in MRONJ-like lesions, however, the mechanisms underlying their therapeutic effects remain unclear. This study investigated the efficacy of the therapeutic effect of fluvastatin (FS) in a rat MRONJ-like model, with particular attention to macrophage polarization. Four-week-old female rats were allocated to three groups. Two groups received zoledronic acid (ZOL) and dexamethasone (DEX) for two weeks prior to extraction of maxillary first molars. After extraction, one group was treated with a single local injection of FS near the extraction site, whereas the other received saline. A control group underwent identical procedures, but received saline instead of ZOL, DEX, and FS. All animals were evaluated two weeks after treatment. The control (saline) group showed complete socket healing. In contrast, ZOL/DEX-treated rats exhibited incomplete epithelial closure and exposed necrotic bone. However, local FS administration in ZOL/DEX-treated rats extensively promoted healing, resulting in smaller epithelial gaps and reduced bone exposure, and decreased areas of necrotic bone. Total macrophage numbers were significantly higher in both experimental groups compared with the control group. The ZOL/DEX group showed a predominance of pro-inflammatory M1 macrophages, whereas the FS-treated group exhibited relatively increased proportions of tissue-reparative M2 macrophages. Local FS administration enhances bone healing of MRONJ-like lesions by promoting macrophage polarization toward M2 phenotype.

Open article ↗



2026-08-29 | Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ.

Sunitinib is a widely used multi-target tyrosine kinase inhibitor associated with side effects that may impair tissue repair and regeneration, potentially contributing to the onset of medication-related osteonecrosis of the jaw. Macrophages play a central role in tissue homeostasis and regeneration, and their dysfunction may be a key factor in this pathological process. In this study, a zebrafish tail fin injury regeneration model was used to investigate the effects of sunitinib on macrophage function and tissue regeneration. Transcriptomic analysis, immunofluorescence staining, RT-qPCR, and Seahorse mitochondrial stress assays were performed to elucidate the underlying mechanisms. Sunitinib treatment significantly impaired macrophage migration and tissue regeneration in a concentration-dependent manner. Transcriptomic analysis revealed that sunitinib markedly suppressed the PPARγ signaling pathway, reparative gene programs, and mitochondrial metabolism. The density of PPARγ+ macrophages at the wound site was significantly reduced following sunitinib exposure. Treatment with rosiglitazone, a PPARγ agonist, effectively rescued the regeneration defects induced by sunitinib, restored macrophage infiltration, and recovered oxidative phosphorylation. Notably, these rescuing effects were abolished upon macrophage depletion. Our results demonstrate that sunitinib impairs tissue regeneration by suppressing PPARγ signaling and oxidative phosphorylation in macrophages. Targeting the PPARγ pathway represents a promising therapeutic strategy to reverse sunitinib-associated deficits in tissue repair.

Open article ↗



proteins
2026-09-03 | Efficacy of concentrated growth factors preventing medication-related osteonecrosis of the jaw following tooth extraction in patients on intravenous bisphosphonates: A randomized controlled trial.

Medication-related osteonecrosis of the jaw (MRONJ) constitutes a severe postoperative complication following tooth extraction in patients with intravenous bisphosphonates (BPs) exposure. This study aimed to evaluate concentrated growth factors (CGF) in preventing MRONJ and enhancing tissue healing after tooth extraction in intravenous BPs treated patients. This randomized controlled trial enrolled 119 patients (150 extraction sites). Extraction sites were randomly allocated to minimally invasive extraction alone (control, N = 75) or with CGF (test, N = 75). MRONJ incidence was assessed at least 8 weeks postoperatively. Gingival buccolingual width and fissure area were measured immediately after extraction and at 1, 2, and 4 weeks postoperatively. In the total cohort and the intravenous BPs combined with denosumab cohort, the incidence of MRONJ in the test group was significantly lower than that in the control group (P =0.028 and P=0.022, respectively). The test group showed significantly greater reduction in postoperative gingival buccolingual width at 1, 2 and 4 weeks and gingival fissure area at 1 and 2 weeks compared to controls (P < 0.05). MRONJ patients had greater intravenous BPs injection times than those without MRONJ (P < 0.001). Minimally invasive tooth extraction with CGF may effectively reduce the risk of MRONJ and promote tissue healing in patients treated with intravenous BPs, particularly those receiving concomitant denosumab therapy.

Open article ↗



2026-08-19 | Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw.

Medication-related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive and antiangiogenic therapies. Prolonged suppression of bone remodeling has been implicated as a key mechanism in its pathophysiology. Teriparatide, an osteoanabolic agent that restores coupled bone remodeling, has been proposed as a potential therapeutic strategy. This review aimed to synthesize reported clinical outcomes of teriparatide use in MRONJ within a systemic remodeling-based framework. We conducted a structured descriptive review based on a systematic literature search and reported in accordance with PRISMA 2020. Studies reporting therapeutic use of teriparatide in established MRONJ were included regardless of the triggering medication. Data were extracted on patient characteristics, MRONJ stage, lesion site, antiresorptive exposure, teriparatide regimen, antiresorptive interruption, antiresorptive type, and clinical outcomes. Because of substantial heterogeneity in study design, patient populations, co-interventions, and outcome reporting, evidence was synthesized qualitatively. Thirty-four publications including 207 patients were included. Clinical outcomes were available for 201 patients: complete coverage/healing was reported in 163, partial improvement in 24, no change in 12, and worsening in 2. Teriparatide discontinuation or dropout after treatment initiation was reported in 13 patients. Stage 2 disease predominated among stageable cases, mandibular involvement was the most frequent anatomical site, and daily teriparatide dosing was more commonly reported than weekly regimens. Bisphosphonate exposure predominated, whereas denosumab-associated cases were fewer; therefore, differential effectiveness by antiresorptive class could not be determined. Published reports describe frequent clinical improvement after teriparatide use in MRONJ. However, the evidence remains descriptive, heterogeneous, and commonly confounded by concomitant therapies. These findings support a biologically plausible remodeling-based interpretation but do not establish efficacy or define teriparatide as standard therapy.

Open article ↗



2026-07-29 | Should Teriparatide Be Part of Our Clinical Armamentarium in the Management of Medication-Related Osteonecrosis of the Jaw? A Systematic Review and Meta-Analysis.

Medication-related osteonecrosis of the jaw (MRONJ) is a severe and potentially debilitating drug reaction. Adjunctive treatments including pentoxifylline, tocopherol, and teriparatide (TPTD) have been studied, but TPTD's efficacy remains unclear. This systematic review and meta-analysis aims to consolidate and evaluate high-quality evidence on TPTD in managing MRONJ. An electronic search strategy was performed on 3 databases (Pubmed, Embase, and Cochrane CENTRAL). Search terms include ("Teriparatide" OR "TPTD" OR "Recombinant Parathyroid Hormone" OR "Recombinant PTH") AND ("Medication-Related Osteonecrosis of the Jaw" OR "MRONJ" OR "BRONJ"). No publication date range was utilized. Inclusion criteria include randomized controlled trials, case-control studies, and cohort studies. All systematic reviews, case reports, case series, animal studies, editorials, non-English publications, or studies relating to osteoradionecrosis were excluded. Each study was screened independently, followed by final study selection after discussion with all authors. Primary meta-analysis used Cox proportional hazards regression with pseudo-individual-subject data reconstructed from published Kaplan-Meier curves (Guyot method) and a Tierney events + P value derivation for one study without Kaplan-Meier data. A sensitivity analysis pooled odds ratios (ORs) at the 6-month clinical response endpoint. Primary outcomes include improvement in MRONJ clinical staging. Secondary outcomes include time to improvement, adverse effects, radiographic evaluation, and presence of serum markers. After review of 162 studies, 5 (3.1%) studies were included in the systematic review with 3 (1.9%) studies included in the meta-analysis (n = 101 subjects). A three-study Cox hazard ratio (HR) meta-analysis yielded a pooled HR of 5.35 (95% CI, 3.14 to 9.13, P < .0001, I2 = 0%) favoring TPTD. Subgroup analyses by dosing regimen showed directionally consistent effects (daily pooled HR = 12.52; 95% CI, 5.75 to 27.23; weekly pooled HR = 8.09; 95% CI, 3.59 to 18.26; both I2 = 0%), and an OR-based sensitivity analysis at the 6-month binary healing endpoint was directionally concordant (pooled OR = 14.26; 95% CI, 2.83 to 71.77). Adjunctive TPTD shows improvement of MRONJ staging and time to healing compared to conventional treatments alone, but the magnitude of the impact remains unclear. Additional evidence, including studies evaluating dosing regimens and subject segmentation by MRONJ staging, is warranted.

Open article ↗



2026-07-11 | Pharmacological and surgical predictors of postoperative healing in medication-related osteonecrosis of the jaw: A retrospective multicenter cohort study.

Failure to achieve postoperative healing after surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) remains a clinical challenge. We aimed to investigate the independent predictors of postoperative nonhealing and to evaluate the impact of regenerative adjuncts. In a multicenter surgical cohort (2019-2025) of 531 patients with MRONJ, pharmacological, lesion level, and surgical factors were assessed using univariable testing, elastic net regularization for variable selection, and multivariable logistic regression. Postoperative nonhealing was defined as the need for additional surgical intervention or failure to achieve complete mucosal coverage, accompanied by clinical or radiographic evidence of persistent or progressive disease. Kaplan-Meier analysis was used to estimate nonhealing-free survival. The overall postoperative nonhealing rate was 18.5% (98/531). In the multivariable models, high-dose antiresorptive therapy (odds ratio [OR]: 2.94, 95% confidence interval [CI]: 1.70-5.06) and multiple-site lesions (OR: 2.29, 95% CI: 1.09-4.67) were independent risk factors for postoperative nonhealing, whereas intraoperative bone morphogenetic protein (BMP) use was associated with a lower risk of postoperative nonhealing (OR: 0.32, 95% CI: 0.20-0.52). The number needed to treat to prevent one postoperative nonhealing event was 5.3 (95% CI: 3.9-8.7) for BMP, and the number needed to harm was 4.4 (95% CI: 3.0-8.5) for high-dose therapy. Solitary maxillary lesions showed an insignificant protective effect. Antiangiogenic agents were associated with postoperative nonhealing in the univariate and elastic net analyses, but not in the final multivariable model. Neither treatment duration nor preoperative drug holiday was independently associated with postoperative nonhealing. The elastic net model showed acceptable discrimination (area under the curve [AUC]: 0.724), and the Kaplan-Meier curves were consistent with these findings. Postoperative nonhealing after surgical management of MRONJ was mainly associated with systemic pharmacological burden and lesion extent, whereas BMP application was associated with improved postoperative healing. These findings support further investigation of regenerative adjuncts and risk-adapted surgical management strategies.

Open article ↗



2026-05-22 | Synergistic application of concentrated growth factor and bone perforation technique in bisphosphonate-related-osteonecrosis of the jaw.

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication caused by the deposition of bisphosphonates in bone tissue, particularly after invasive dental procedures. Its pathogenesis is closely related to impaired bone remodeling and insufficient blood supply. Optimizing treatment strategies for BRONJ remains a significant clinical challenge. This study aims to evaluate the therapeutic effects of concentrated growth factor (CGF) combined with the bone perforation technique in the treatment of BRONJ. A rat model of BRONJ was established and divided into four groups: Non-treated group (N), Bone perforation group (B), CGF group (C), and CGF + Bone perforation group (C + B). Bone repair was evaluated at 2 and 4 weeks post-treatment through micro-computed tomography (Micro-CT), histological analysis (HE and TRAP staining), Western blot, immunofluorescence staining, and qRT-PCR (RUNX2, ALP). HE staining at 2 weeks postoperatively showed abundant empty lacunae with inflammation in the N and B groups, while the C and C + B groups exhibited reduced necrotic bone and new bone formation. At 4 weeks, the C + B group achieved complete epithelial healing with no residual necrotic bone. Quantitative histomorphometry revealed that the TRAP-positive area was 0.32% in the C group and 0.27% in C + B groups, significantly higher than that in the N group 0.12%(p < 0.001). PCR analyses revealed that, at 2 weeks, ALP expression was highest in the C group compared to all other groups (N, B, and C + B) (p < 0.001), whereas RUNX2 expression showed no significant difference between the C and C + B groups but was significantly higher than that in the N and B groups (p < 0.01). At 4 weeks, the C + B group exhibited the highest ALP and RUNX2 expression, significantly exceeding all other groups (N, B, and C). Western blot analyses demonstrated that at 2 weeks post-surgery, ALP and RUNX2 protein expression was higher in the C group than in all other groups (p < 0.05). At 4 weeks, ALP expression was higher in the C and C + B groups compared to the other groups (p < 0.001). RUNX2 expression was highest in the C + B group (p < 0.001). Our results demonstrate that CGF significantly promotes BRONJ repair, while the bone perforation technique improves early blood supply but has limited long-term therapeutic effects. The combined application of CGF and bone perforation exerts a synergistic effect in enhancing osteogenesis and optimizing bone repair outcomes. Future studies with larger sample sizes and longer follow-up periods are warranted to verify these findings.

Open article ↗



cell therapies
2026-08-09 | Individualized 3D-Printed Titanium Mesh-Assisted Alveolar Reconstruction and Implant Rehabilitation Following MRONJ Resection: A Case Report.

Medication-related osteonecrosis of the jaw is a severe complication of antiresorptive therapy that often necessitates complex reconstructive surgery. This report describes a case of implant-supported rehabilitation using a customized 3D-printed titanium mesh for an extensive mandibular defect resulting from medication-related osteonecrosis of the jaw. A 58-year-old woman with stage-3 medication-related osteonecrosis of the jaw after zoledronate therapy underwent segmental mandibulectomy and reconstruction with a free iliac crest graft. Nine months later, a customized titanium mesh was placed to protect the planned 9.5-11 mm augmentation. Cone beam computed tomography confirmed mineralized regeneration within the mesh. The mesh was removed after achieving 9.5 mm vertical and 11 mm horizontal alveolar augmentation, and 4 implants were placed with high primary stability (insertion torque ≥ 40 N cm). At 6 months, resonance frequency analysis values ranged from 75 to 84, allowing delivery of a splinted fixed prosthesis. At 12 months of loading, the peri-implant tissues remained normal with stable radiographic bone levels and satisfactory function. Combining customized 3D-printed titanium mesh with guided implant placement supports stable bone regeneration and prosthetic rehabilitation in patients with medication-related osteonecrosis of the jaw. However, outcomes depend on medication history, therapy timing, and unresolved drug-related factors, underscoring the need for a multidisciplinary approach with individualized treatment and proactive complication care.

Open article ↗



2026-07-31 | [A retrospective study of pedicled flaps for repair of oral mucosal defects in patients with medication-related osteonecrosis of the jaw].

Objective: To investigate the clinical efficacy of pedicled flaps for repairing oral mucosa defects in medication-related osteonecrosis of the jaw (MRONJ), and to analyze the indications for different types of pedicled flaps. Methods: The clinical data of 158 MRONJ patients who met the inclusion criteria and were admitted to the Department of Maxillofacial Trauma and Orthognathic Surgery, Hospital of Stomatology, Air Force Medical University from January 2019 to December 2024 were retrospectively analyzed, including 74 males (46.8%) and 84 females (53.2%).The mean age was (59.2±10.7) years (range, from 20 to 87 years old). According to the method of soft tissue repair, the patients were divided into direct suture group (61 cases) and pedicled tissue flap group (97 cases, including 80 cases of buccal fat pad flap and 17 cases of submental island flap). The rate of secondary operation was compared between the two groups. Multivariate binary Logistic regression and subgroup analysis were used to evaluate the efficacy and influencing factors of pedicled tissue flaps, and the comparison between the buccal fat pad flap and submental island flap was performed. Results: The median follow-up time was 36 months. Univariate analysis showed that the secondary operation rate was 68.9% (42/61) in the direct suture group, which was significantly higher than 16.5% (16/97) in the pedicled tissue flap group (P<0.001). After adjusting for confounding factors such as age and lesion location, multivariate Logistic regression analysis showed that pedicled tissue flap was an independent protective factor against the risk of secondary surgery (OR=0.049, P<0.001). Stage 3 disease was an independent risk factor for secondary surgery (OR=8.455, P=0.002). Subgroup analysis showed that the secondary operation rate of pedicled tissue flap was significantly lower than that of direct suture in stage 3 group, mandibular group,<65 years group, male group and female group (all P<0.05). There was no significant difference among stage 2 group, maxillary group and≥65 years group (all P>0.05), but the trend of protection was the same. The secondary operation rate was 17.5% (14/80) in the buccal fat pad flap group and 2/17 in the submental island flap group. There was no significant difference between the two groups (P=0.730). Conclusions: The use of pedicled tissue flap for repairing oral mucosal wounds can significantly reduce the risk of secondary surgery for MRONJ, and the effect is superior to direct suture. Buccal fat pad flap is the first choice for maxillary and retromolar mucosal defects, and submental island flap can be used for large mandibular mucosal defects.

Open article ↗



2026-07-31 | [Research progress of mesenchymal stem cells in the treatment of medication-related osteonecrosis of the jaw].

Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication characterized primarily by jawbone necrosis, induced by bisphosphonates or other targeted agents for systemic diseases. With the advancement of systemic anticancer therapies, the survival of patients with advanced malignancies has been prolonged, leading to an annual increase in the number of patients with MRONJ. However, there is currently no effective treatment for MRONJ worldwide. Recent studies have indicated that mesenchymal stem cells exhibit significant potential for osteogenic and angiogenic differentiation, proliferation, immunomodulation, and anti-inflammatory effects, thereby providing a novel therapeutic strategy for medication-related osteonecrosis of the jaw. This article reviews the research on mesenchymal stem cell therapy for MRONJ, providing a reference for its clinical research and treatment.

Open article ↗



2026-06-01 | Human Amniotic Membrane as Adjuvant Therapy in Medication-Related Osteonecrosis of the Jaw: A Scoping Review

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication characterized by progressive destruction of the maxillary and mandibular bones in patients receiving antiresorptive or antiangiogenic agents. Despite evolving clinical guidelines, its management remains controversial and nonstandardized. Human amniotic membrane (HAM) has emerged as a promising adjuvant therapy due to its immunomodulatory, anti-inflammatory, and regenerative properties. Objective: To identify and synthesize available evidence on the effectiveness of HAM as an adjuvant treatment in promoting wound healing in patients diagnosed with MRONJ. Methods: A scoping review was conducted following the PRISMA-ScR framework. Searches were performed in PubMed/MEDLINE, Scopus, and Web of Science using MeSH terms and free-text keywords including “amniotic membrane,” “amnion,” “bisphosphonate-associated osteonecrosis,” and “medicationrelated osteonecrosis of the jaw,” combined with Boolean operators. Searches were limited to primary human studies published within the past five years. Results: A total of 25 records were identified; after deduplication and screening, 3 primary studies were included comprising a total of 39 patients across various MRONJ stages. Across all studies, 83.8% of patients achieved complete mucosal wound closure, and 84.6% reported a significant reduction in pain perception. No adverse events, recurrences, or infectious complications were reported. Conclusions: HAM represents a viable, versatile, and effective adjuvant intervention in the surgical management of MRONJ. It promotes soft-tissue healing, reduces pain and infection, and favorably impacts patient prognosis and quality of life. Randomized controlled trials with larger samples and standardized protocols are warranted.

Open article ↗



2026-05-20 | Mesenchymal stem cell therapy for treatment of medication related osteonecrosis of the jaw (MRONJ): A systematic review.

Medication-related osteonecrosis of the jaw (MRONJ) is a significant adverse effect associated with antiresorptive and antiangiogenic therapies. Therapies utilizing mesenchymal stem cells (MSCs) represent a promising regenerative strategy; however, conventional management methods have shown limited effectiveness. This systematic review aimed to evaluate the effectiveness of MSC-based interventions in preventing and treating MRONJ. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science to identify studies published from 2011 to 2024. Studies examining MSCs therapy in the context of MRONJ were incorporated according to predefined inclusion and exclusion criteria. Seventeen studies (6 clinical, 11 preclinical) met inclusion criteria. Preclinical models demonstrated that MSCs enhance angiogenesis and bone regeneration, providing mechanistic support for human application. Clinically, 80-90% of patients achieved complete mucosal healing with radiographic evidence of bone regeneration. However, due to species differences in oral microbiome and immunity, animal findings require confirmation in human trials. This review integrates human clinical data with mechanistic insights from preclinical studies. Human evidence shows promising mucosal and bone regeneration, while animal studies elucidate underlying mechanisms-particularly angiogenesis and immunomodulation. Given that animal models cannot replicate the human oral immune environment, these findings should be interpreted as hypothesis-generating. MSC therapy represents a biologically sound but experimental strategy, warranting confirmation through randomized controlled trials.

Open article ↗



other
2025-12-11 | The Mitigating Effect and Mechanism of Polydeoxyribonucleotide Against Zoledronic Acid-Induced Growth Suppression of Human Gingival Fibroblasts.

Zoledronic acid (ZA), a nitrogen-containing bisphosphonate, is widely used to treat osteoporosis and bone metastases. However, its clinical application is limited by adverse effects, notably bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is associated with cytotoxicity in oral mucosal cells. Polydeoxyribonucleotide (PDRN), a salmon sperm-derived DNA polymer with regenerative and anti-inflammatory properties, has shown therapeutic potential in tissue repair; however, its ability to mitigate ZA-induced cytotoxicity remains poorly understood. Here, we investigated the molecular mechanisms of ZA-induced toxicity in HGF-1 cells, a human gingival fibroblast line, and evaluated the protective effects of PDRN. ZA treatment (50 µM, 48 h) significantly inhibited HGF-1 cell growth, accompanied by reduced phosphorylation of protein kinase B (PKB) and signal transducer and activator of transcription 3 (STAT-3), along with increased phosphorylation of TANK-binding kinase 1 (TBK1). TBK1 silencing restored cell growth under ZA exposure, whereas silencing PKB or STAT-3 further suppressed cell growth even without ZA. Co-treatment with PDRN (100 µg/mL) effectively prevented and reversed ZA-induced HGF-1 cytotoxicity. Mechanistically, PDRN inhibited ZA-induced TBK1 phosphorylation and partially restored PKB phosphorylation, though it did not reverse the reduction in p-STAT-3. Additionally, ZA significantly elevated intracellular reactive oxygen species (ROS) levels at 8 h, which were attenuated by PDRN. The antioxidant N-acetylcysteine (NAC) similarly reduced ZA-induced ROS and p-TBK1 levels and improved cell growth, although it had limited effects on p-PKB at 8 h. Importantly, delayed PDRN treatment following ZA exposure reversed ZA-induced cell growth inhibition and TBK1 activation in a dose- and time-dependent manner. In summary, these findings demonstrate that ZA suppresses HGF-1 cell growth through ROS production, TBK1 activation, and inhibition of PKB and STAT-3, whereas PDRN counteracts these effects primarily by suppressing TBK1 activation and oxidative stress.

Open article ↗



2025-09-02 | Rethinking Osteonecrosis of the Jaw: Could Cellular Senescence Be the Missing Link Between ORN and MRONJ?

Osteonecrosis of the jaw (ONJ) is a series bone diseases characteristic with similar diagnostic criteria and clinical manifestations. Phossy jaws, medication-related osteonecrosis of the jaw (MRONJ), and osteoradionecrosis (ORN) are major subtypes of ONJ. Though subtypes of ONJ are considered different diseases in clinical practice, similar diagnostic criteria, clinical presentation, and features prompt the possibility that there is a common pathogenesis mechanism for ONJ subtypes. Current pathogenic theories fail to fully explain the delayed onset, persistent progression, and stimulus-independent nature of ONJ. Here, we propose that cellular senescence could be a common pathogenesis mechanism of ONJ. Radiation, antiresorptive agents, and trauma induce persistent DNA damage and activate the DNA damage response, leading to irreversible senescence in jawbone cells. This model explains key clinical observations and offers a rationale for the failure of stimulus withdrawal to reverse disease progression. We outline future directions to validate this hypothesis. If confirmed, this hypothesis may unify ONJ subtypes under a single pathogenic framework and open avenues for targeted interventions.

Open article ↗



2024-10-16 | Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare side effect of antiresorptive drugs that significantly hinders the quality of life of affected patients. The disease develops in the presence of a combination of factors. Important pathogenetic factors include inflammation, inhibition of bone remodeling, or genetic predisposition. Since the first description of this rare side effect in 2003, a growing body of data has suggested a possible role for genetic factors in the disease. Several genes have been suggested to play an important role in the pathogenesis of MRONJ such as SIRT1, VEGFA, and CYP2C8. With the development of molecular biology, newer methods such as miRNA and gene expression studies have been introduced in MRONJ, in addition to methods that can examine the base sequence of the DNA. Describing the complex genetic background of MRONJ can help further understand its pathophysiology as well as identify new therapeutic targets to better manage this adverse drug reaction.

Open article ↗



2024-07-09 | Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate.

Zoledronate (ZA) stands as a highly effective antiresorptive agent known to trigger medication-related osteonecrosis of the jaw (MRONJ). Its clinical dosages primarily encompass those used for oncologic and osteoporosis treatments. While inflammation is recognized as a potential disruptor of mucosal healing processes associated with ZA, prior research has overlooked the influence of varying ZA dosages on tissue adaptability. Therefore, a deeper understanding of the specific mechanisms by which inflammation exacerbates ZA-induced MRONJ, particularly when inflammation acts as a risk factor, remains crucial. Cell proliferation and migration of human oral keratinocytes (HOK) was analyzed after treatment with different doses of ZA and/or lipopolysaccharide (LPS) to assess their possible effect on mucosal healing of extraction wounds. Mouse periodontitis models were established using LPS, and histological changes in extraction wounds were observed after the administration of oncologic dose ZA. Hematoxylin and eosin (HE) staining and immunofluorescence were used to evaluate mucosal healing. In vitro, LPS did not exacerbate the effects of osteoporosis therapeutic dose of ZA on the proliferation and migration of HOK cells, while aggravated these with the oncologic dose of ZA treatment by inducing mitochondrial dysfunction and oxidative stress via regulating SIRT1 expression. Furthermore, SIRT1 overexpression can alleviate this process. In vivo, local injection of LPS increased the nonunion of mucous membranes in MRONJ and decreased the expression of SIRT1, PGC-1α, and MnSOD. Inflammation aggravates oncologic dose of ZA-induced mitochondrial dysfunction and oxidative stress via a SIRT1-dependent pathway, enhancing the risk of impaired mucosal healing in MRONJ. Our study implies that inflammation becomes a critical risk factor for MRONJ development at higher ZA concentrations. Elucidating the mechanisms of inflammation as a risk factor for mucosal non-healing in MRONJ could inform the development of SIRT1-targeted therapies.

Open article ↗



2023-11-13 | Exosome-targeted delivery of METTL14 regulates NFATc1 m6A methylation levels to correct osteoclast-induced bone resorption

Abstract Osteoporosis has a profound influence on public health. First-line bisphosphonates often cause osteonecrosis of the jaw meanwhile inhibiting osteoclasts. Therefore, it is important to develop effective treatments. The results of this study showed that the increased level of NFATc1 m6A methylation caused by zoledronic acid (ZOL), with 4249A as the functional site, is highly correlated with the decreased bone resorption of osteoclasts. Upstream, METTL14 regulates osteoclast bone absorption through the methylation functional site of NFATc1. Downstream, YTHDF1 and YTHDF2 show antagonistic effects on the post-transcriptional regulation of NFATc1 after the m6A methylation level is elevated by METTL14. In this study, meRIP-Seq, luciferase reporter assays, meRIP and other methods were used to elucidate the NFATc1 regulatory mechanism of osteoclasts from the perspective of RNA methylation. In addition, EphA2 overexpression on exosomes is an effective biological method for targeted delivery of METTL14 into osteoclasts. Importantly, this study shows that METTL14 released by exosomes can increase the m6A methylation level of NFATc1 to inhibit osteoclasts, help postmenopausal osteoporosis patients preserve bone mass, and avoid triggering osteonecrosis of the jaw, thus becoming a new bioactive molecule for the treatment of osteoporosis.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

1 orphan drug designation for Osteonecrosis of the jaw.

1 orphan drug designation for Osteonecrosis of the jaw.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Recombinant human platelet derived growth factor BB

proteins

FDA
2007-02-01

—

Luitpold Pharmaceuticals, Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.